Rise Therapeutics, LLC
R-5280, a butyrylated and acetylated resistant starch therapeutic to modulate gut microbiome and immune response in Type 1 diabetes
- Sector
- Biotech
- Headquarters
- Rockville, MD
- Total capital
- $32.6M
- Federal grants
- $32.6M
- 39 awards · 2018–2025
- Rank in peer group#2 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 2 pending · first 2024
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$953K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$828K
- Federal grantHealth and Human S · Phase II · R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$996K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$915K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$956K
- Federal grantHealth and Human S · Phase II · A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$171K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$987K
Show 32 earlier federal awards
- Federal grantHealth and Human S · Phase II · A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$984K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$494K
- Federal grantHealth and Human S · Phase II · R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$1M
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$1M
- Federal grantHealth and Human S · Phase II · A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$984K
- Federal grantHealth and Human S · Phase II · A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$828K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$306K
- Federal grantHealth and Human S · Phase II · A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$1M
- Federal grantHealth and Human S · Phase II · A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$923K
- Federal grantHealth and Human S · Phase II · A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$78K
- Federal grantHealth and Human S · Phase I · A Novel Probiotic Drug Delivery Platform for Oral Administration of Protein-Based Therapies$283K
- Federal grantHealth and Human S · Phase II · A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$361K
- Federal grantHealth and Human S · Phase II · A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$1M
- Federal grantHealth and Human S · Phase II · A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$1M
- Federal grantHealth and Human S · Phase II · A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$973K
- Federal grantHealth and Human S · Phase II · A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$30K
- Federal grantHealth and Human S · Phase II · A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$459K
- Federal grantHealth and Human S · Phase II · A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$25K
- Federal grantHealth and Human S · Phase II · A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$1M
- Federal grantHealth and Human S · Phase II · A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$914K
- Federal grantHealth and Human S · Phase II · A Novel Probiotic for the Treatment of Sjogren's Syndrome$2.9M
- Federal grantHealth and Human S · Phase I · A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$387K
- Federal grantHealth and Human S · Phase II · A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$896K
- Federal grantHealth and Human S · Phase II · A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$1M
- Federal grantHealth and Human S · Phase II · A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$2.8M
- Federal grantHealth and Human S · Phase II · A Novel Probiotic for the Treatment of Sjogren's Syndrome$950K
- Federal grantHealth and Human S · Phase II · A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$892K
- Federal grantHealth and Human S · Phase I · A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease$217K
- Federal grantHealth and Human S · Phase II · A Novel Probiotic for the Treatment of Sjogren's Syndrome$1.9M
- Federal grantHealth and Human S · Phase I · A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease$300K
- Federal grantHealth and Human S · Phase I · A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$480K
- Federal grantHealth and Human S · Phase I · A novel Probiotic for Preventing and Treating Clostridium Difficile Pathogenesis$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#2 · top 1%
- Granted patents#186 · top 36%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 3- PendingSurface Layer Protein A (slpa) As A Therapeutic Agent For The Treatment Of Inflammatory DiseasesUSPTOApplication 18891070
- GrantedSurface Layer Protein A (slpa) As A Therapeutic Agent For The Treatment Of Inflammatory DiseasesUSPTOUS 12,098,170
- PendingSurface Layer Protein A (slpa) As A Therapeutic Agent For The Treatment Of Inflammatory DiseasesUSPTOApplication PCTUS2022032938
Related companies, and why
- Provenance Group, Inc.Similar federal contract value in Biotech · null in contracts
- HELIGENICS INCSimilar federal contract value in Biotech · null in contracts
- Dayi Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Faraday BiosciencesSimilar federal contract value in Biotech · null in contracts
- Capra Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Skylark BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .